Top

Current Anesthesiology Reports

Published in:

01-06-2020 | Heart Surgery | Blood Management (KA Tanaka, Section Editor)

Factor Concentrate-Based Approaches to Blood Conservation in Cardiac Surgery: European Perspectives in 2020

Authors: Daniel Bolliger, Marcus D. Lancé

Published in: Current Anesthesiology Reports | Issue 2/2020

Abstract

Purpose of Review

Recent European guidelines and expert consensus statements recommend the use of coagulation factor concentrates to improve hemostasis in bleeding patients after cardiac surgery and for patient blood management. This review summarizes the current evidence relating to coagulation management with the help of coagulation factor concentrates as supported by many European experts and institutes.

Recent Findings

Maintaining a postoperative fibrinogen level > 1.5–2 g/l by administering fibrinogen concentrate in hypofibrinogenemic bleeding patients has been suggested. Likewise, the use of low-dose four-factor prothrombin complex concentrates seems to be relatively safe in bleeding patients. In contrast, the use of recombinant factor VIIa and factor XIII concentrates has been discouraged due to questionable benefit and potentially impaired outcome.

Summary

The use of coagulation factor concentrates is preferred over the allogeneic blood products in anticipation of a better outcome in many European cardiac surgical centers. However, it remains unclear whether the use of coagulation factor concentrates such as fibrinogen concentrates or four-factor prothrombin complex concentrates is actually associated with better patient outcome.

• Bolliger D, Tanaka KA. Coagulation management in cardiac surgery. Curr Anesthesiol Rep. 2017;7:265–72 Recent narrative review on the recent advantages in perioperative hemostasis management in bleeding patients after cardiac surgery.

Alstrom U, Granath F, Friberg O, Ekbom A, Stahle E. Risk factors for re-exploration due to bleeding after coronary artery bypass grafting. Scand Cardiovasc J. 2012;46:39–44.PubMed

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013;118:40–50.PubMed

Fassl J, Matt P, Eckstein F, et al. Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometry-guided transfusion management. J Cardiothorac Vasc Anesth. 2013;27:1181–8.PubMed

• Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117:531–47 The first large randomized controlled trial showing the benefits of point-of-care guided administration of coagulation factor concentrate in cardiac surgery. PubMed

Biancari F, Kinnunen EM, Kiviniemi T, Tauriainen T, Anttila V, Airaksinen JKE, et al. Meta-analysis of the sources of bleeding after adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018;32:1618–24.PubMed

Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010;113:1205–19.PubMed

Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, Crowther MA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg. 2010;110:1533–40.PubMed

Raspe C, Besch M, Charitos EI, et al. Rotational thromboelastometry for assessing bleeding complications and factor XIII deficiency in cardiac surgery patients. Clin Appl Thromb Hemost. 2018;24(9 Suppl):136S–44S.PubMedCentral

10.

Tanaka KA, Esper S, Bolliger D. Perioperative factor concentrate therapy. Br J Anaesth. 2013;111(Suppl 1):i35–49.PubMed

11.

Mazzeffi MA, Chriss E, Davis K, Zhan M, Harris A, Rock P, et al. Optimal plasma transfusion in patients undergoing cardiac operations with massive transfusion. Ann Thorac Surg. 2017;104:153–60.PubMed

12.

Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth. 2012;26:1083–93.PubMed

13.

Meybohm P, Herrmann E, Steinbicker AU, Wittmann M, Gruenewald M, Fischer D, et al. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient's outcome: a prospective, multicenter cohort study with a noninferiority design. Ann Surg. 2016;264:203–11.PubMed

14.

Bolliger D, Buser A, Tanaka KA. Transfusion requirements in anesthesia and intensive care. Curr Anesthesiol Rep. 2019;9:194–201.

15.

•• Mazer CD, Whitlock RP, Shehata N. Restrictive versus liberal transfusion for cardiac surgery. N Engl J Med. 2018;379:2576–7 Largest randomized trial on hemoglobin triggers for red blood cell transfusion in cardiac surgery patients. PubMed

16.

Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015;372:997–1008.PubMed

17.

Bolliger D, Buser A, Erb JM. Patient blood management in cardiac surgery. Curr Anesthesiol Rep. 2019;9:215–22.

18.

•• Boer C, Meesters MI, Milojevic M, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018;32:88–120 Recent guidelines on patient blood management in cardiac surgery based on a systematic review. PubMed

19.

• Erdoes G, Koster A, Meesters MI, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia. 2019;74:1589–600 A recent narrative consensus statement on the use of fibrinogen concentrate in cardiac surgery by different European experts.PubMed

20.

Fassl J, Lurati Buse G, Filipovic M, Reuthebuch O, Hampl K, Seeberger MD, et al. Perioperative administration of fibrinogen does not increase adverse cardiac and thromboembolic events after cardiac surgery. Br J Anaesth. 2015;114:225–34.PubMed

21.

Gorlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology. 2011;115:1179–91.PubMed

22.

• Ranucci M, Baryshnikova E, Crapelli GB, et al. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc. 2015;4:e002066 In this randomized controlled trial, the authors showed that supplementation with fibrinogen concentrate reduces the use of allogeneic blood products after cardiac surgery. PubMedPubMedCentral

23.

Gorlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth. 2013;27:S20–34.PubMed

24.

Tanaka KA, Bader SO, Sturgil EL. Diagnosis of perioperative coagulopathy - plasma versus whole blood testing. J Cardiothorac Vasc Anesth. 2013;27:S9–15.PubMed

25.

Bolliger D, Tanaka KA. Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery. Transfus Med Rev. 2013;27:213–20.PubMed

26.

Gorlinger K, Dirkmann D, Solomon C, Hanke AA. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br J Anaesth. 2013;110:222–30.PubMed

27.

Spalding GJ, Hartrumpf M, Sierig T, Oesberg N, Kirschke CG, Albes JM. Cost reduction of perioperative coagulation management in cardiac surgery: value of “bedside” thrombelastography (ROTEM). Eur J Cardiothorac Surg. 2007;31:1052–7.PubMed

28.

Althoff FC, Neb H, Herrmann E, Trentino KM, Vernich L, Füllenbach C, et al. Multimodal patient blood management program based on a three-pillar strategy: a systematic review and meta-analysis. Ann Surg. 2019;269:794–804.PubMed

29.

Kozek-Langenecker S, Sorensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care. 2011;15:R239.PubMedPubMedCentral

30.

• Carson JL, Triulzi DJ, Ness PM. Indications for and adverse effects of red cell transfusion. N Engl J Med. 2017;377:1261–72 Recent excellent review on the risk of adverse events with RBC transfusion. PubMed

31.

Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology. 2011;115:635–49.PubMedPubMedCentral

32.

Mazzeffi M, Chriss E, Tanaka K. Time for a fresh approach to examining factors associated with red blood cell transfusion outcome. Anesth Analg. 2018;127:1271–4.PubMed

33.

Agudelo-Jimenez RD, Heatter JA, Cata JP. Transfusion therapy: is there a link with cancer recurrence? Curr Anesthesiol Rep. 2018;8:426–38.

34.

Wikkelso A, Wetterslev J, Moller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017;72:519–31.PubMed

35.

Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995;81:360–5.PubMed

36.

Callum J, Farkouh ME, Scales DC, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial. JAMA. 2019;322:1966–76 1–11.PubMedCentral

37.

Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23:98.PubMedPubMedCentral

38.

Li JY, Gong J, Zhu F, Moodie J, Newitt A, Uruthiramoorthy L, et al. Fibrinogen concentrate in cardiovascular surgery: a meta-analysis of randomized controlled trials. Anesth Analg. 2018;127:612–21.PubMed

39.

Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev. 2012;26:1–13.PubMed

40.

Ranucci M, Baryshnikova E. Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST). Br J Anaesth. 2016;116:618–23.PubMed

41.

Ranucci M, Di Dedda U, Baryshnikova E. Trials and tribulations of viscoelastic-based determination of fibrinogen concentration. Anesth Analg. 2019;130:644–53.

42.

Ogawa S, Szlam F, Bolliger D, Nishimura T, Chen EP, Tanaka KA. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg. 2012;115:16–21.PubMed

43.

Taketomi T, Szlam F, Vinten-Johansen J, Levy JH, Tanaka KA. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagul Fibrinolysis. 2007;18:761–7.PubMed

44.

• Grottke O, Levy JH. Prothrombin complex concentrates in trauma and perioperative bleeding. Anesthesiology. 2015;122:923–31 An recent excellently written narrative review on the use of prothrombin complex concentrates in the perioperative setting.PubMed

45.

DeAngelo J, Jarrell D, Cosgrove R, Camamo J, Edwards C, Patanwala AE. Comparison of 3-factor versus 4-factor prothrombin complex concentrate with regard to warfarin reversal, blood product use, and costs. Am J Ther. 2018;25:e326–e32.PubMed

46.

• Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43 In this randomized controlled trial, the benefits of prothrombin complex concentrates for reversal of vitamin K antagonists were shown. PubMedPubMedCentral

47.

Milling TJ Jr, Refaai MA, Sarode R, et al. Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med. 2016;23:466–75.PubMedPubMedCentral

48.

Pollock KA, McMillan Z, Pretorius GD, Cronin B. Low cardiac output after orthotopic heart transplant secondary to large inferior vena cava thrombus after prothrombin complex: a case report. A A Case Rep. 2017;8:43–6.PubMed

49.

Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99:251–60.PubMed

50.

Enter DH, Zaki AL, Marsh M, et al. Prothrombin complex concentrate reduces blood product utilization in heart transplantation. Pharmacotherapy. 2017;37:1215–20.PubMed

51.

Sun GH, Patel V, Moreno-Duarte I, Zahedi F, Ursprung E, Couper G, et al. Intraoperative administration of 4-factor prothrombin complex concentrate reduces blood requirements in cardiac transplantation. J Cardiothorac Vasc Anesth. 2018;32:161–7.PubMed

52.

Wanek MR, Hodges K, Persaud RA, Lam SW, Soltesz EG, Tong MZ, et al. Prothrombin complex concentrates for warfarin reversal before heart transplantation. Ann Thorac Surg. 2019;107:1409–15.PubMed

53.

Bhatt HV, Subramaniam K. PRO: Prothrombin complex concentrate should be used in preference to fresh frozen plasma for hemostasis in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2018;32:1062–7.PubMed

54.

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.PubMed

55.

Guzzetta NA, Szlam F, Kiser AS, et al. Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass. Br J Anaesth. 2014;112:319–27.PubMed

56.

Percy CL, Hartmann R, Jones RM, Balachandran S, Mehta D, Dockal M, et al. Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2015;26:357–67.PubMedPubMedCentral

57.

•• Roman M, Biancari F, Ahmed AB, et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg. 2019;107:1275–83 The most recent and complete meta-analysis on the use of prothrombin complex concentrates in cardiac surgery showing reduction in the transfusion of allogeneic blood products without markedly increased thromboembolic risk. PubMed

58.

Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care. 2016;20:5.PubMedPubMedCentral

59.

Fitzgerald J, Lenihan M, Callum J, McCluskey S, Srinivas C, van Rensburg A, et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. Br J Anaesth. 2018;120:928–34.PubMed

60.

Biancari F, Ruggieri VG, Perrotti A, et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart Lung Circ. 2019;28:1881–7.PubMed

61.

Zweng I, Galvin S, Robbins R, et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart Lung Circ. 2019;28:1706–13.PubMed

62.

Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg. 2001;93:287–9.PubMed

63.

von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002;16:615–6.

64.

Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg. 2005;28:254–8.PubMed

65.

Karkouti K, Beattie WS, Wijeysundera DN, Yau TM, McCluskey S, Ghannam M, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26–34.PubMed

66.

Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80:66–71.PubMed

67.

Karkouti K, Beattie WS, Crowther MA, Callum JL, Chun R, Fremes SE, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anaesth. 2007;54:573–82.PubMed

68.

Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008;118:331–8.PubMed

69.

Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007;83:707–14.PubMed

70.

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, et al. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg. 2008;85:836–44.PubMed

71.

Mitra B, Phillips L, Cameron PA, Billah B, Reid C. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care. 2010;38:671–7.PubMed

72.

Alfirevic A, Duncan A, You J, Lober C, Soltesz E. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg. 2014;98:618–24.PubMedPubMedCentral

73.

Bolliger D, Tanaka KA. Tranexamic acid in vascular surgery: Antifibrinolytic or clot-stabilising activity. Br J Anaesth. 2020;124:4–6.PubMed

74.

Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg. 2006;54:26–33.PubMed

75.

Karkouti K, von Heymann C, Jespersen CM, Korte W, Levy JH, Ranucci M, et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg. 2013;146:927–39.PubMed

76.

Levy JH, Gill R, Nussmeier NA, Olsen PS, Andersen HF, Booth FV, et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report. Thromb Haemost. 2009;102:765–71.PubMed

77.

Strauss ER, Mazzeffi MA, Williams B, Key NS, Tanaka KA. Perioperative management of rare coagulation factor deficiency states in cardiac surgery. Br J Anaesth. 2017;119:354–68.PubMed

78.

Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion. 2008;48:2152–8.PubMed

79.

Desborough MJ, Oakland K, Brierley C, et al. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev. 2017;7:CD001884.PubMed

80.

Swieringa F, Lance MD, Fuchs B, et al. Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding. J Thromb Haemost. 2015;13:1503–13.PubMed

81.

Desborough MJ, Oakland KA, Landoni G, Crivellari M, Doree C, Estcourt LJ, et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2017;15:263–72.PubMed

Title: Factor Concentrate-Based Approaches to Blood Conservation in Cardiac Surgery: European Perspectives in 2020
Authors: Daniel Bolliger
Marcus D. Lancé
Publication date: 01-06-2020
Publisher: Springer US
Keywords: Heart Surgery
Heart Surgery
Published in: Current Anesthesiology Reports / Issue 2/2020
Electronic ISSN: 2167-6275
DOI: https://doi.org/10.1007/s40140-020-00382-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Factor Concentrate-Based Approaches to Blood Conservation in Cardiac Surgery: European Perspectives in 2020

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2020

Patient Blood Management in Adult Extracorporeal Membrane Oxygenation Patients

Incidence and Risk Factors for Postoperative Residual Neuromuscular Blockade

Local Anesthetic Systemic Toxicity (LAST) – a Review and Update

Anesthetic Challenges in Treating the Older Adult Trauma Patient: an Update

Evaluation of the Efficacy and Safety of Neostigmine in Reversing Neuromuscular Blockade

Deep Neuromuscular Blockade: Does the Data Support Its Use in Surgical Patients?